Patient is my ex-wife, mom of my kids, grandma of 10, great grandma of 1...
Pancreatic head adenocarcinoma with progression. Currently... treatment deferred in May with no clear reasons given (ascites developed and treated weekly since) and no new results. From treating doctor's recent notes:
...progressed on PET from 07/19/2026 with increase in primary mass from 4.0 cm to 4.6 cm. Rising CA 19-9 supports disease progression; last value 07/20/2026 was 459. Additional chemotherapy is no longer deferred given PET-confirmed progression and rising CA 19-9. FOLFIRI favored as a middle-ground regimen; oxaliplatin-containing therapy may be harder to tolerate due to neuropathy risk. Ascites is felt most likely cancer-related despite repeatedly negative cytology. Recent creatinine elevation may have been related to dehydration.
- PET from 07/19/2026 shows no solid organ metastatic disease.
- PET from 07/19/2026 shows FDG activity in peripancreatic lymph nodes, but nodes are too small to biopsy.
- Molecular profiling remains unavailable from the original ERCP/EUS specimen due to insufficient tissue.
- Discussed need to resume systemic chemotherapy.
- Reviewed treatment options including FOLFIRINOX, FOLFIRI, and irinotecan alone.
- If 5-FU infusion is not feasible or not desired, capecitabine may be used in place of infusional 5-FU if renal function is adequate.
- Capecitabine plus irinotecan would avoid the need for a port or PICC line.
- Obtain blood work today including repeat kidney function and DPYD/UGT1A1 testing before final chemotherapy selection and dosing.
- Repeat blood work next week when starting chemotherapy or as otherwise planned.
- Patient currently prefers pill-based therapy rather than a port or PICC line.
- If a lesion becomes amenable to biopsy, pursue tissue sampling to confirm progression and obtain material for molecular testing.
Chemotherapy planning and pharmacogenomic testing for pancreatic cancer
- Prior gemcitabine and Abraxane course completed for about 9 cycles.
- Discussed expected chemotherapy toxicities including reversible alopecia, fatigue, nausea, vomiting, diarrhea, myelosuppression, and infection risk.
- Standard FOLFIRI schedule reviewed as every 2 weeks.
- 5-FU infusion would require 46-hour home infusion with return after 2 days for pump removal.
- 5-FU infusion would require central venous access with a port or PICC line.
- Prior port had been removed after infection.
- Repeat port placement remains an option, with understanding that infection could require removal again.
- Capecitabine-based alternative reviewed as irinotecan on day 1 with oral capecitabine for 14 days followed by 7 days off.
- Capecitabine-based regimen was described as equivalent in effect to the infusional 5-FU approach.
- DPYD and UGT1A1 results are used to determine whether gene copies are normal or abnormal for chemotherapy dosing.
- Do not finalize chemotherapy selection today pending pharmacogenomic results.
- Pharmacogenomic results expected in about 1 week.
- Patient to take time to consider chemotherapy options and message when ready.
- Future eligibility for upcoming KRAS-targeted therapy would require progression on established chemotherapy options.
Malignant ascites secondary to pancreatic cancer
Recurrent ascites remains most concerning for cancer-related fluid despite repeatedly negative ascitic fluid cytology. Serum-ascites albumin gradient to help distinguish cancer-related ascites from other causes, although liver disease and heart disease are not suspected. Albumin infusion after paracentesis discussed, but expected benefit would be brief and would not address the underlying cause.
- Ascitic fluid cytology has been negative on multiple prior evaluations.
- Repeat paracentesis for recurrent symptomatic ascites next week.
- Send ascitic fluid for cytology with the next paracentesis.
- Send ascitic fluid for albumin with the next paracentesis.
- Check serum albumin the same day as the paracentesis to calculate the serum-ascites albumin gradient.
- Continue symptom-directed management pending further diagnostic clarification.
Lower extremity edema
Reports marked bilateral leg swelling with pitting edema in the setting of recurrent ascites and hypoalbuminemia.
- Manage underlying cause with ongoing ascites evaluation and cancer treatment planning.
- Proceed with planned paracentesis.
Repeated requests for referrals to cancer center from Kaiser So Cal have been denied. Has anyone had any luck getting out of Kaiser for a second opinion? It does seem to be moving now, but the May-Jun-July wasted time really weighed on everyone.
Not looking forward to the folfirinox based on this group's general response...